- Trials with a EudraCT protocol (780)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
780 result(s) found for: covid-19.
Displaying page 2 of 39.
EudraCT Number: 2020-001459-42 | Sponsor Protocol Number: 26223678Hans | Start Date*: 2020-04-22 | |||||||||||
Sponsor Name:Zealand University Hospital | |||||||||||||
Full Title: Ruxolitinib Treatment in Patients with Severe COVID-19 Infection. A Danish Safety and Efficacy Study. | |||||||||||||
Medical condition: COVID-19 Pneumonia Severly afflicted COVID-19 infected patients in respirator or in the time window with urgent need of respirator before intubation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001434-35 | Sponsor Protocol Number: Hydroxycholoquin-COVID-19 | Start Date*: 2020-03-31 |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Monocentric Population Pharmacokinetic study of Hydroxychloroquine in COVID-19 Patients to inform its dosing optimization. | ||
Medical condition: Subject tested positive for COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001202-30 | Sponsor Protocol Number: NL73618.100.20 | Start Date*: 2021-05-04 |
Sponsor Name:Diakonessenhuis | ||
Full Title: SARS-CoV-2 immune response | ||
Medical condition: immune response to COVDI-19 vaccination | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000905-26 | Sponsor Protocol Number: CoVaCan-01 | Start Date*: 2021-03-31 |
Sponsor Name:Department of Oncology, Uppsala University Hospita | ||
Full Title: Immune response to Covid-19 vaccination in patients with immune modulatory treatment for cancer | ||
Medical condition: Immune response to Covid-19 vaccination of patients with immune modulatory treatment for cancer | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000413-17 | Sponsor Protocol Number: COVERS | Start Date*: 2021-02-24 |
Sponsor Name:Region Skåne - Kliniska Studier Sverige, Forum Söder | ||
Full Title: COVERS (COVID-Vaccination Efficiency Risk and Safety Study) - an open trial for follow-up of efficacy, risk and safety in persons who have been vaccinated against SARS-CoV-2 in Region Skåne with va... | ||
Medical condition: Coronavirus disease 2019 (COVID-19) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001103-32 | Sponsor Protocol Number: HEPCOViVac | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: The HEPCOViVac Registry - Immunological response in patients with liver disease vaccinated against COVID-19 | ||
Medical condition: Cirrhotic chronic liver disease | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-001459-15 | Sponsor Protocol Number: HS-2021-02 | Start Date*: 2021-04-26 |
Sponsor Name:Medical University of Graz | ||
Full Title: Immune response to COVID-19 Vaccination in people with Diabetes Mellitus - COVAC-DM study | ||
Medical condition: Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: AT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001501-24 | Sponsor Protocol Number: IRST100.47 | Start Date*: 2020-04-28 | |||||||||||
Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS | |||||||||||||
Full Title: PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). | |||||||||||||
Medical condition: Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patients Group 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situation | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003643-29 | Sponsor Protocol Number: VAC31518COV3009 | Start Date*: 2020-11-10 | |||||||||||
Sponsor Name:Janssen Vaccines & Prevention B.V. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Assess the Efficacy and Safety of Ad26.COV2.S for the Prevention of SARS-CoV-2-mediated COVID-19 in Adults Aged 18 Years and Older E... | |||||||||||||
Medical condition: Healthy Volunteers, with or without comorbidities (Prevention of SARS-CoV-2-mediated COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) FR (Ongoing) DE (Ongoing) ES (Temporarily Halted) BE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002123-11 | Sponsor Protocol Number: HUIS-04-2020 | Start Date*: 2020-05-07 | |||||||||||
Sponsor Name:Tatiana Cobo Ibáñez [...] | |||||||||||||
Full Title: EFFICACY OF CYCLOSPORINE IN THE TREATMENT OF COVID-19 PNEUMONIA: A RANDOMIZED CONTROLLED TRIAL. | |||||||||||||
Medical condition: COVID-19 PNEUMONIA | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001938-19 | Sponsor Protocol Number: mdc-TTG-CT-002 | Start Date*: 2022-03-10 | |||||||||||
Sponsor Name:MedinCell S.A. | |||||||||||||
Full Title: A multicentre randomised, Double-Blind, Placebo-controlled, Study to evaluate the efficAcy and safety of oral IVErmectin tablets in the prevention of COVID-19 (the SAIVE Trial) | |||||||||||||
Medical condition: Prophylaxis of COVID-19 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000683-30 | Sponsor Protocol Number: CoVacc | Start Date*: 2021-03-03 |
Sponsor Name:Umeå university | ||
Full Title: CoVacc - Immune response to vaccination against Covid-19, an open multicenter phase IV study | ||
Medical condition: Individuals with and without pre-existing immunity to Covid-19. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: SE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2021-000454-26 | Sponsor Protocol Number: 76702 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Leiden University Medical Center | |||||||||||||
Full Title: Establishing the safety, tolerability and immunogenicity of intradermal delivery of mRNA SARS-CoV-2 vaccine in healthy adults | |||||||||||||
Medical condition: Healthy volunteers | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002857-28 | Sponsor Protocol Number: C4671002 | Start Date*: 2021-08-23 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2 ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF 07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTI... | |||||||||||||
Medical condition: Coronavirus Disease 2019 (COVID-19) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Restarted) HU (Completed) BG (Completed) CZ (Completed) SK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-000904-39 | Sponsor Protocol Number: MK-4482-013 | Start Date*: 2021-08-11 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of MK-4482 for the Prevention of COVID-19 (Laboratory-confirmed SARS-CoV-2 Infection W... | |||||||||||||
Medical condition: Prophylaxis of COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Prematurely Ended) HU (Completed) BG (Ongoing) RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001678-31 | Sponsor Protocol Number: APHP200462 | Start Date*: 2020-04-28 |
Sponsor Name:Assistance Publique Hopitaux de Paris | ||
Full Title: Randomized controlled trial evaluating the efficacy of vaccination with Bacillus Calmette and Guérin (BCG) in the Prevention of COVID-19 via the strengthening of innate immunity in Health Care Work... | ||
Medical condition: COVID 19 Health care workers (medical or non-medical) in French hospitals in direct contact with COVID-19 patients, including nurses, medical doctors and other personnel working in wards in charge... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001527-14 | Sponsor Protocol Number: 1 | Start Date*: 2020-04-21 |
Sponsor Name:Erasmus MC | ||
Full Title: COVID-19: addition of azithromycin to chloroquine treatment | ||
Medical condition: COVID-19 | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-001010-38 | Sponsor Protocol Number: Ahus-NO-COVID-19 | Start Date*: 2020-03-23 | |||||||||||
Sponsor Name:Akershus University Hospital | |||||||||||||
Full Title: NORWEGIAN CORONAVIRUS DISEASE 2019 (NO COVID-19) STUDY: AN OPEN LABELED RANDOMIZED CONTROLLED PRAGMATIC TRIAL TO EVALUATE THE ANTIVIRAL EFFECT OF CHLOROQUINE IN ADULT PATIENTS WITH SARS-COV-2 INFEC... | |||||||||||||
Medical condition: SARS-COV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001421-31 | Sponsor Protocol Number: QUINAVID-19 | Start Date*: 2020-04-06 | |||||||||||
Sponsor Name:Sociedad Española de Farmacia Hospitalaria | |||||||||||||
Full Title: Clinical trial randomized, unblinded and controled for evaluation of efficacy and safety of hydroxychloroquine chemoprophylaxis against SARS-CoV-2 (COVID-19) infection in healthcare professionals. | |||||||||||||
Medical condition: SARS-CoV-2 infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-002613-34 | Sponsor Protocol Number: NL76336.041.21 | Start Date*: 2021-06-30 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: Prospective monitoring of antibody response following COVID-19 vaccination in patients with Down Syndrome | ||
Medical condition: Persons with Down syndrome | ||
Disease: | ||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
